HC Wainwright Has Positive Estimate for HRMY Q2 Earnings

Key Points

• HC Wainwright has raised its Q2 2026 earnings estimate for Harmony Biosciences to $1.16 per share, up from a prior estimate of $1.01, while maintaining a "Buy" rating with a $55.00 price target.
• Several analysts have adjusted their ratings and target prices for Harmony Biosciences, with estimates ranging from $33.00 to $54.00 among different firms.
• Harmony Biosciences reported a 16.0% increase in quarterly revenue year-over-year, despite missing earnings expectations in their latest results.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Investment analysts at HC Wainwright boosted their Q2 2026 earnings estimates for shares of Harmony Biosciences in a report issued on Thursday, September 25th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $1.16 per share for the quarter, up from their prior estimate of $1.01. HC Wainwright has a "Buy" rating and a $55.00 price objective on the stock. The consensus estimate for Harmony Biosciences' current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Harmony Biosciences' Q3 2026 earnings at $1.25 EPS, FY2028 earnings at $7.21 EPS and FY2029 earnings at $7.43 EPS.

Other equities analysts have also issued research reports about the company. Needham & Company LLC cut their target price on Harmony Biosciences from $48.00 to $41.00 and set a "buy" rating on the stock in a research note on Wednesday. The Goldman Sachs Group began coverage on shares of Harmony Biosciences in a research note on Thursday, July 10th. They issued a "neutral" rating and a $33.00 target price for the company. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Harmony Biosciences from $54.00 to $36.00 and set a "buy" rating for the company in a report on Thursday. Truist Financial assumed coverage on Harmony Biosciences in a report on Monday, July 21st. They set a "buy" rating and a $48.00 target price on the stock. Finally, Mizuho dropped their price target on Harmony Biosciences from $50.00 to $35.00 and set an "outperform" rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, Harmony Biosciences has a consensus rating of "Buy" and an average price target of $45.50.

Harmony Biosciences Price Performance

HRMY opened at $27.04 on Friday. The company has a fifty day moving average price of $35.08 and a two-hundred day moving average price of $33.41. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.80 and a current ratio of 3.84. The firm has a market capitalization of $1.56 billion, a PE ratio of 8.72, a P/E/G ratio of 0.31 and a beta of 0.84. Harmony Biosciences has a 52 week low of $26.35 and a 52 week high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 earnings per share for the quarter, missing analysts' consensus estimates of $0.78 by ($0.10). Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%.The business had revenue of $200.49 million for the quarter, compared to the consensus estimate of $204.37 million. During the same period last year, the firm earned $1.05 earnings per share. The company's quarterly revenue was up 16.0% on a year-over-year basis. Harmony Biosciences has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Harmony Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Financial Management Professionals Inc. acquired a new stake in shares of Harmony Biosciences in the first quarter valued at about $29,000. Brooklyn Investment Group raised its stake in shares of Harmony Biosciences by 1,031.9% during the 1st quarter. Brooklyn Investment Group now owns 1,064 shares of the company's stock worth $35,000 after purchasing an additional 970 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Harmony Biosciences by 4,185.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,157 shares of the company's stock worth $37,000 after purchasing an additional 1,130 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Harmony Biosciences in the 1st quarter valued at approximately $57,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Harmony Biosciences by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,218 shares of the company's stock valued at $70,000 after buying an additional 299 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.